A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity

PHASE2RecruitingINTERVENTIONAL

Enrollment

141

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

September 24, 2026

Study Completion Date

February 11, 2027

Conditions

ObesityHeart Failure With Preserved Ejection Fraction (HFPEF)Heart Failure With Mildly Reduced Ejection Fraction

Interventions

OTHER

placebo

placebo administered subcutaneously(SC), once a week

DRUG

IBI362

IBI362 administered subcutaneously(SC), once a week

Trial Locations (1)

RECRUITING

Fuwai Hospital, CAMS&PUMC, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06862908 - A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity | Biotech Hunter | Biotech Hunter